Singapore, March 5 -- Boehringer Ingelheim's biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a regulatory reform promoting segmented manufacturing of biological products by the local authorities. The reform, led by the Chinese medicine authority NMPA (National Medical Products Administration), aims at enhancing control, efficiency, and flexibility in the production process.

As one of the few contract manufacturing organisations qualified for the pilot period, Boehringer Ingelheim BioXcellence is expanding its service portfolio in China, offering distinct service packages for different segments in biopharmaceutical production and enabling the sustainable global supply of medications to patients.

Boeh...